High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 744-750

  Yu, Ke ^a   Geng, Xingchao ^b   Chen, Minjun ^a   Zhang, Jie ^a   Wang, Bingshun ^c   Ilic, Katarina ^d   Tong, Weida ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPIDEM; BENOXAPROFEN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DICLOFENAC; DISULFIRAM; EFAVIRENZ; ENTACAPONE; FENOFIBRATE; FLUCONAZOLE; IBUPROFEN; ISONIAZID; KETOCONAZOLE; MERCAPTOPURINE; MOXIFLOXACIN; TICLOPIDINE; TOLCAPONE; TROVAFLOXACIN; UNINDEXED DRUG; VALPROIC ACID; ZOLPIDEM;

ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG METABOLISM; ENZYME INDUCTION; ENZYME SUBSTRATE; HUMAN; LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; REFERENCE DATABASE; SYSTEMATIC REVIEW; TOXIC HEPATITIS;

ADMINISTRATION, ORAL; CYTOCHROMES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; HUMANS; LOGISTIC MODELS; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; SUBSTRATE SPECIFICITY;

EID: 84896135679     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.056267     Document Type: Article

References (33)

1. Banks AT, Zimmerman HJ, Ishak KG, and Harter JG (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22:820-827.
2. Chen M, Borlak J, and Tong W (2013a) High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 58:388-396.
3. Chen M, Vijay V, Shi Q, Liu Z, Fang H, and Tong W (2011) FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 16:697-703.
4. Chen M, Zhang J, Wang Y, Liu Z, Kelly R, Zhou G, Fang H, Borlak J, and Tong W (2013b) The liver toxicity knowledge base: a systems approach to a complex end point. Clin Pharmacol Ther 93:409-412.
5. Helfgott SM, Sandberg-Cook J, Zakim D, and Nestler J (1990) Diclofenac-associated hepatotoxicity. JAMA 264:2660-2662.
6. Hollenberg PF (2002) Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 34:17-35.
7. Ibáñez L, Pérez E, Vidal X, and Laporte JR; Grup d'Estudi Multicènteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB) (2002) Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 37:592-600.
8. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, and Lemasters JJ (2002) Mechanisms of hepatotoxicity. Toxicol Sci 65:166-176. (Pubitemid 34121108)
9. Javier Rodríguez-González F, Montero JL, Puente J, Fraga E, Costán G, Barrera P, Muntané J, De la Mata M, and Zambrana JL (2002) Orthotopic liver transplantation after subacute liver failure induced by therapeutic doses of ibuprofen. Am J Gastroenterol 97:2476-2477.
10. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, and Nakai Y, et al. (2005) A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 6:161-225. (Pubitemid 40753853)
11. Keisu M and Andersson TB (2010) Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 196:407-418.
12. Kirchheiner J and Brockmöller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1-16. (Pubitemid 40089477)
13. Lee WM, Squires RH, Jr, Nyberg SL, Doo E, and Hoofnagle JH (2008) Acute liver failure: Summary of a workshop. Hepatology 47:1401-1415. (Pubitemid 351547926)
14. Li AP (2002) A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 142:7-23.
15. Lin JH, Chen IW, Chiba M, Nishime JA, and Deluna FA (2000) Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: involvement of enzyme inactivation. Drug Metab Dispos 28:460-466. (Pubitemid 30185685)
16. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, and Chavin KD (2003) Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290:1500-1504. (Pubitemid 37430406)
17. Meibohm B, Beierle I, and Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329-342. (Pubitemid 34713088)
18. Mohutsky MA, Romeike A, Meador V, Lee WM, Fowler J, and Francke-Carroll S (2010) Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment. Toxicol Pathol 38:799-809.
19. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, and Williams DP (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 45:177-202. (Pubitemid 40261802)
20. Parkinson A, Mudra DR, Johnson C, Dwyer A, and Carroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193-209. (Pubitemid 39208721)
21. Russo MW, Galanko JA, Shrestha R, Fried MW, and Watkins P (2004) Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 10:1018-1023. (Pubitemid 39232756)
22. Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, and Aleo MD (2011) Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 24:1345-1410.
23. Stine JG, Sateesh P, and Lewis JH (2013) Drug-induced liver injury in the elderly. Curr Gastroenterol Rep 15:299.
24. Tanaka E (1998) Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 23:403-416.
25. Tanaka E (1999) Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 24:339-346.
26. Uetrecht J (2007) Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 47:513-539.
27. U.S. Food And Drug Administration (2009) Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Rockville, MD
28. U.S. Food and Drug Administration (2012) Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling Recommendations, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD.
29. Walgren JL, Mitchell MD, and Thompson DC (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 35:325-361. (Pubitemid 40691298)
30. Wells C and Lever AM (1992) Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge. J Infect 24:111-112.
31. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208. (Pubitemid 39410902)
32. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, and Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988. (Pubitemid 37221681)
33. Zhou SF, Liu JP, and Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89-295.